Palisade Bio, Inc. (NASDAQ: PALI) director Robert Baltera Jr. has increased his direct holdings in the company through a series of recent stock purchases. The transactions, executed on July 1 and July 2, 2026, involved the acquisition of 30,000 shares of common stock. The total value of these acquisitions amounted to $59,400. The shares were purchased at a weighted average price of $1.98 per share, with individual transaction prices ranging from $1.97 to $1.99. Following these purchases, Baltera Jr. directly holds 366,904 shares of Palisade Bio common stock.
The stock currently trades at $2.04, which is near its 52-week high of $2.85. Over the past year, the stock has delivered a remarkable 181% return despite significant volatility. According to InvestingPro analysis, the stock appears overvalued at current levels, with a FAIR financial health rating. Investors can access 12 additional InvestingPro Tips and comprehensive metrics to make more informed decisions about PALI.
In other recent news, Palisade Bio has received FDA clearance to initiate a Phase 2 clinical trial for its investigational drug PALI-2108, aimed at treating moderately to severely active ulcerative colitis. This global trial, named ASCENTRA-UC, is expected to enroll up to 204 patients across North America and Europe, with enrollment anticipated to begin in the second half of 2026. Primary efficacy results are projected for the second half of 2027. H.C. Wainwright has reiterated a Buy rating for Palisade Bio, maintaining a price target of $7.00 following the FDA's clearance. Additionally, Palisade Bio recently presented pharmacokinetic data for PALI-2108, indicating promising steady-state concentrations of its active metabolite. The company has also strengthened its Board of Directors by appointing Robert Baltera and Jordan Zwick, both of whom bring extensive biotech expertise. Baltera's background includes leadership roles at Amira Pharmaceuticals and board positions at multiple companies, including Imago BioSciences.